PMDI 财务： Psychemedics Corp AI 分析

主页

股票

PMDI

财务数据

PMDI 财务

Psychemedics Corp

$1.6

11.88%

$0.17

截至今日：Mar 26, 15:30:08 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

PMDI 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	19	19	22	25	24	21
营收同比增长 (YoY)	-14%	-14%	-12%	4%	14%	-43%
营收成本	12	12	13	15	14	16
毛利润	7	7	8	9	10	4
销售、一般及管理费用	8	8	10	9	8	9
研发	0	0	1	1	1	1
营业费用	8	8	11	10	10	10
其他非经营性收入 (费用)	0	0	0	0	--	--
税前利润	-1	-1	-3	-1	0	-6
所得税费用	0	0	0	0	0	-2
净利润	-1	-1	-4	-1	0	-3
净利润增长	-75%	-75%	300%	--	-100%	-400%
稀释后流通股数	5.98	5.86	5.74	5.63	5.55	5.52
股份同比变动 (YoY)	3%	2%	2%	1%	1%	0%
每股收益 (摊薄)	-0.31	-0.31	-0.72	-0.19	-0.12	-0.7
每股收益增长率	-56%	-56%	281%	57.99%	-83%	-350%
自由现金流	0	0	-1	4	0	-5
每股自由现金流	--	--	--	--	--	--
毛利率	36.84%	36.84%	36.36%	36%	41.66%	19.04%
营业利润率	-5.26%	-5.26%	-9.09%	-4%	0%	-28.57%
净利率	-5.26%	-5.26%	-18.18%	-4%	0%	-14.28%
自由现金流利润率	0%	0%	-4.54%	16%	0%	-23.8%
EBITDA	0	0	-1	1	2	-4
EBITDA 利润率	0%	0%	-4.54%	4%	8.33%	-19.04%
EBITDA 中的折旧与摊销	1	1	1	2	2	2
EBIT	-1	-1	-2	-1	0	-6
EBIT 利润率	-5.26%	-5.26%	-9.09%	-4%	0%	-28.57%
有效税率	0%	0%	0%	0%	0%	33.33%

Follow-Up Questions

Psychemedics Corp 的关键财务报表是什么？



根据最新的财务报表（Form-10K），Psychemedics Corp 的总资产为 $8，净损失为 $-1

PMDI 的关键财务比率是什么？



Psychemedics Corp 的流动比率是 2.66，净利 margin 为 -5.26，每股销售为 $3.23。

Psychemedics Corp 的收入按细分市场或地理位置如何划分？



Psychemedics Corp 最大收入来源是 Testing，在最近的收益报告中收入为 18,661,000。就地区而言， United States 是 Psychemedics Corp 的主要市场，收入为 21,216,000。

Psychemedics Corp 是否盈利？



不，根据最新的财务报表，Psychemedics Corp 的净损失为 $-1

Psychemedics Corp 有负债吗？



是的，Psychemedics Corp 的负债为 3

Psychemedics Corp 的流通股有多少？



Psychemedics Corp 的总流通股为 6.11

关键数据

前收盘价

$1.43

开盘价

$1.53

当日区间

$1.53 - $1.6

52周范围

$1.37 - $2.4

交易量

1.9K

平均成交量

3.2K

股息收益率

0.00%

每股收益（TTM）

-0.32

市值

$9.7M

什么是 PMDI？

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. The company is headquartered in Acton, Massachusetts and currently employs 101 full-time employees. The firm provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The firm customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The firm markets its corporate drug testing services through its own sales force, distributors, and partners. The company markets its home drug testing service, PDT-90, through the Internet.

功能特性

资源